Clinical trial
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the…
NCT01231347 · NantCell, Inc., Industry · Completed
Key facts
| NCT number | NCT01231347 |
|---|---|
| Title | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas |
| Official title | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas |
| Acronym | GAMMA |
| Lead sponsor | NantCell, Inc., Industry |
| Collaborators | Takeda Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas, Cancer of the Pancreas, Metastases, Metastatic Cancer, Metastatic Pancreatic Cancer, Pancreas Cancer, Pancreatic Cancer and 6 more |
| Intervention type | Drug |
| Interventions | AMG 479, Placebo, gemcitabine |
| Enrollment | 800 |
| Start date | Apr 7, 2011 |
| Primary completion | Dec 12, 2012 |
| Completion | Dec 12, 2012 |
| First posted | Nov 1, 2010 |
| Last update posted | Jul 16, 2024 |
| Countries | Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Greece and 20 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: